MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Xencor Inc

Abierto

SectorSanidad

10.63 -0.47

Resumen

Variación precio

24h

Actual

Mínimo

10.18

Máximo

10.91

Métricas clave

By Trading Economics

Ingresos

-5.7M

-54M

Ventas

59M

70M

BPA

-0.62

Margen de beneficios

-77.303

Empleados

250

EBITDA

27M

-16M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+172.14% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-370M

747M

Apertura anterior

11.1

Cierre anterior

10.63

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Xencor Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Alphabet, Intel, AppFolio

24 abr 2025, 23:51 UTC

Charlas de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 abr 2025, 23:37 UTC

Principales Noticias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 abr 2025, 23:36 UTC

Principales Noticias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 abr 2025, 23:13 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 abr 2025, 23:09 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 22:48 UTC

Principales Noticias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 abr 2025, 22:47 UTC

Charlas de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 abr 2025, 22:38 UTC

Charlas de Mercado
Ganancias

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 abr 2025, 22:24 UTC

Charlas de Mercado
Ganancias

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 abr 2025, 22:23 UTC

Ganancias

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 abr 2025, 22:09 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 abr 2025, 22:00 UTC

Charlas de Mercado
Ganancias

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 abr 2025, 21:39 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 abr 2025, 21:23 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 abr 2025, 21:04 UTC

Ganancias

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 abr 2025, 21:02 UTC

Ganancias

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparación entre iguales

Cambio de precio

Xencor Inc previsión

Precio Objetivo

By TipRanks

172.14% repunte

Estimación a 12 Meses

Media 29.5 USD  172.14%

Máximo 38 USD

Mínimo 22 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xencor Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

0

Mantener

1

Vender

Puntuación técnica

By Trading Central

10.81 / 10.87Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.